About Us

Our Science

KatheraBio’s antifungal technology targets cellular enzymes that play an essential role in pathways regulating fungal growth and pathogenicity. Chemical genomic experiments indicate that the enzymes are also critically important for fungal cell wall biosynthesis and/or stress responses. We believe that targeting these cellular enzymes and pathways will lead to opportunities to develop innovative next generation antifungal monotherapies, or agents that can be used in combination therapies to synergistically treat infections caused by drug-resistant fungi.  To learn more about our science, contact us.

Contact Us

Our Management Team

Keith A Bostian PhD

Founder, Board Member, Acting-CEO

Linkedin
Stephen Parent PhD

Founder, Acting Board Member, Vice President, Business Strategy & Development

Linkedin
Steven Hanes PhD

Founder, Acting Board Member, Chief Scientific Officer

Linkedin
Robert McLaughlin PhD

Founder, Acting - Vice President, Research and Development

Linkedin
James Balkovec PhD

Founder, Acting - Vice President, Chemistry

Linkedin

Our Scientific Advisory Board

Steven Hanes PhD

Chief Scientific Officer, Chair of Scientific Advisory Board

Linkedin
Dave Perlin
David Perlin PhD

Chief Scientific Officer/Senior Vice President, Hackensack Meridian Health, Discovery & Innovation

Linkedin

Our Consultants Advisory Board

Ving Lee PhD

Founding Consultant (Medicinal Chemist, VJL Med Chem Consultants LLC)

Linkedin
Michael S. Cosgrove PhD

Structural Biologist, Biochemistry & Molecular Biology, Department, SUNY-Upstate Medical University

Linkedin
Richard Tschirret-Guth PhD

Enzymologist, DMPK Chemist, Living Water DMPK Consulting LLC

Linkedin

Licensing and Corporate Development Advisors

Thomas Richardson PhD

President, ILSE

Linkedin
AJAY
Ajay Kumar PhD

Vice President Project & Alliance Mnagement, ILSE

Linkedin
Scroll to Top